Lab Results
What Is an Optimal Lipoprotein(a) Level?: A Functional-Medicine Interpretation Guide
Lipoprotein(a) — often abbreviated Lp(a) — is one of the most underordered cardiovascular risk markers in routine blood work, yet elevated levels are present in roughly 20% of the global population and are almost entirely genetically determined. Standard reference labs flag Lp(a) as normal below 75 nmol/L (or 30 mg/dL), but functional-medicine practitioners and major cardiology societies are now calling for a far stricter threshold. Understanding where your number falls — and which companion markers like CRP, fibrinogen, and HbA1c amplify that risk — is the first step toward a genuinely personalized cardiovascular strategy.
Why Lipoprotein(a) Is the Cardiovascular Marker Your Doctor Probably Skipped
Lipoprotein(a), or Lp(a), is a low-density lipoprotein particle with an extra glycoprotein called apolipoprotein(a) wrapped around it. That structural quirk makes it dramatically more atherogenic than standard LDL: it promotes plaque formation, inhibits fibrinolysis, and carries oxidized phospholipids that drive arterial inflammation — all at the same time. Unlike LDL cholesterol, which responds meaningfully to diet and statins, Lp(a) concentration is 70–90% heritable, which is why lifestyle changes alone rarely move the needle significantly (Nordestgaard et al., European Heart Journal 2010; PMID: 20634197).
Despite this, Lp(a) is absent from most annual panels. A 2022 National Lipid Association consensus statement estimated that one in five people worldwide carries an Lp(a) level high enough to confer independent cardiovascular risk — yet the majority have never been tested. That gap between what the science says and what gets ordered is precisely where functional-medicine labs become valuable.
What Is an Optimal Lipoprotein(a) Level? Conventional vs. Functional Thresholds
Units matter here. Lp(a) is reported in either mg/dL or nmol/L, and the two don't convert cleanly because particle size varies between individuals. A rough conversion factor is 1 mg/dL ≈ 2.5 nmol/L, but most leading cardiologists prefer nmol/L because it reflects particle number rather than mass.
| Classification | Lp(a) in mg/dL | Lp(a) in nmol/L | Risk Interpretation |
|---|---|---|---|
| Optimal (functional medicine) | < 14 mg/dL | < 30 nmol/L | Minimal independent risk |
| Acceptable (conventional lab) | < 30 mg/dL | < 75 nmol/L | Low-to-moderate risk |
| Borderline elevated | 30–50 mg/dL | 75–125 nmol/L | Moderate risk; monitor closely |
| High (ESC guideline threshold) | > 50 mg/dL | > 125 nmol/L | High independent CVD risk |
| Very high | > 90 mg/dL | > 200 nmol/L | Severe risk; specialist referral |
The European Society of Cardiology officially recommends that Lp(a) be measured at least once in every adult's lifetime, and the 2019 ESC/EAS dyslipidemia guidelines identify > 50 mg/dL (> 125 nmol/L) as a high-risk threshold that should intensify overall cardiovascular risk management (Mach et al., European Heart Journal 2020; PMID: 31504418).
From a functional-medicine perspective, even the 30–50 mg/dL zone warrants attention when other inflammatory markers are elevated — because Lp(a) does not act in isolation. It amplifies risk in the presence of systemic inflammation, glycemic dysfunction, and endothelial injury. That's why interpreting Lp(a) alongside CRP, fibrinogen, and HbA1c paints a far more complete picture than any single number alone.
What Is an Optimal CRP Level? The Inflammation Multiplier
C-reactive protein (CRP) — particularly the high-sensitivity CRP (hs-CRP) assay — measures systemic low-grade inflammation. When both Lp(a) and hs-CRP are elevated, cardiovascular risk compounds rather than simply adds: the oxidized phospholipids carried on Lp(a) particles directly stimulate hepatic CRP production, creating a reinforcing loop.
Optimal vs. conventional hs-CRP thresholds:
| Classification | hs-CRP (mg/L) | Clinical Context |
|---|---|---|
| Optimal | < 0.5 mg/L | Minimal vascular inflammation |
| Low risk (AHA) | < 1.0 mg/L | Standard low-risk benchmark |
| Average risk | 1.0–3.0 mg/L | Moderate cardiovascular risk |
| High risk | > 3.0 mg/L | High independent CVD risk |
| Acute-phase / infection | > 10 mg/L | Retest after illness resolves |
A landmark JUPITER trial analysis found that patients with LDL < 130 mg/dL but hs-CRP > 2 mg/L had substantially higher rates of major cardiovascular events — and responded to statin therapy in proportion to CRP reduction, not just LDL lowering (Ridker et al., New England Journal of Medicine 2008; PMID: 18997196). Functional-medicine clinicians use this data to argue that hs-CRP below 1.0 mg/L — ideally below 0.5 mg/L — is the true optimization target, not merely "less than 3."
Omega-3 fatty acids (EPA + DHA) are among the best-studied dietary modulators of hs-CRP. A meta-analysis of 18 randomized controlled trials found that omega-3 supplementation significantly reduced CRP, with the most pronounced effects at doses of 2,000 mg EPA/DHA per day or higher (Calder, British Journal of Nutrition 2012; PMID: 22591896).
What Is an Optimal Fibrinogen Level? Clotting Risk Beyond the Standard Panel
Fibrinogen is a clotting protein produced by the liver. Chronically elevated fibrinogen increases blood viscosity, promotes platelet aggregation, and — critically in the context of Lp(a) — directly amplifies thrombotic risk because Lp(a)'s apolipoprotein(a) domain structurally mimics plasminogen and competes with it, impairing the body's ability to dissolve clots.
When both fibrinogen and Lp(a) are elevated, the combination is considered particularly high-risk in advanced lipid panels used in preventive cardiology.
| Classification | Fibrinogen (mg/dL) | Interpretation |
|---|---|---|
| Optimal (functional) | 150–250 mg/dL | Low thrombotic burden |
| Conventional normal | 200–400 mg/dL | Acceptable; watch trends |
| Elevated | 400–600 mg/dL | Increased clotting and CVD risk |
| High | > 600 mg/dL | Significant thrombotic risk |
Fibrinogen rises with infection, smoking, obesity, and metabolic syndrome. Epidemiological data from the Emerging Risk Factors Collaboration (Danesh et al., JAMA 2012; PMID: 22910756) confirmed that higher fibrinogen concentrations were linearly and independently associated with risks of coronary heart disease, stroke, and all-cause mortality after controlling for traditional risk factors. Each 1 g/L increase in fibrinogen was associated with a roughly 2-fold increase in coronary heart disease risk.
Fibrinogen is not commonly ordered on routine panels, but it is included in advanced cardiovascular risk assessments and is frequently elevated in the same metabolic environments that drive high Lp(a) expression — making it a natural companion marker in functional cardiovascular evaluation.
What Is an Optimal HbA1c Level? Glycemic Control as a Cardiovascular Risk Amplifier
HbA1c (glycated hemoglobin) reflects average blood glucose over the prior 2–3 months. It is the primary monitoring tool for diabetes management, but its relevance extends deep into cardiovascular risk — even in people who do not have diabetes. Chronic hyperglycemia accelerates endothelial dysfunction, promotes glycation of LDL and Lp(a) particles, and drives the formation of advanced glycation end-products (AGEs) that stiffen arterial walls.
| Classification | HbA1c (%) | Interpretation |
|---|---|---|
| Optimal (functional) | < 5.3% | Minimal glycation burden |
| Normal (conventional) | < 5.7% | Below diabetes risk threshold |
| Prediabetes | 5.7–6.4% | Elevated metabolic and CVD risk |
| Diabetes | ≥ 6.5% | Diagnosis threshold |
| Controlled diabetes target | < 7.0% | ADA treatment goal |
From a functional-medicine perspective, even HbA1c values in the 5.4–5.7% range represent a zone of concern when paired with elevated Lp(a), because glycated Lp(a) particles appear to be more pro-inflammatory and more resistant to clearance than non-glycated forms. A prospective cohort study found that each 1% increase in HbA1c was associated with a 14% increase in the risk of cardiovascular events, independent of other traditional risk factors (Selvin et al., Annals of Internal Medicine 2010; PMID: 20083827).
The A1C level and Lp(a) level are therefore not independent conversations — they are overlapping risk dimensions that should always be read together when assessing cardiovascular or metabolic health.
Reading the Full Picture: A Functional Cardiovascular Risk Matrix
Functional-medicine practitioners rarely interpret a single biomarker in isolation. Instead, they look at clusters of findings that tell a coherent physiological story. Below is a simplified risk matrix for how Lp(a) interacts with its most important companion markers:
| Lp(a) Status | CRP | Fibrinogen | HbA1c | Risk Interpretation |
|---|---|---|---|---|
| Optimal (< 30 nmol/L) | < 1.0 | < 250 | < 5.3% | Low baseline risk |
| Elevated (> 125 nmol/L) | < 1.0 | < 250 | < 5.3% | Elevated genetic risk; mitigate other factors |
| Elevated | > 3.0 | > 400 | < 5.3% | High inflammatory + thrombotic burden |
| Elevated | > 3.0 | > 400 | 5.7–6.4% | Very high compounded risk — clinical urgency |
| Elevated | > 3.0 | > 400 | ≥ 6.5% | Severe — specialist evaluation required |
Understanding where you fall in this matrix — not just whether your Lp(a) is "in range" — is the foundation of genuinely personalized cardiovascular risk management. To explore how other lipid markers fit into this picture, see our guide to understanding advanced lipid panels and cardiovascular risk.
Can You Lower Lipoprotein(a)? What the Evidence Actually Says
This is where patients often feel frustrated. Because Lp(a) is so strongly genetically determined, most interventions produce only modest reductions. Here is what the current evidence supports:
Lifestyle interventions (diet, exercise, weight loss): Generally produce < 10% reduction in Lp(a). Not insignificant, but insufficient as a standalone strategy for those in the high-risk zone.
Niacin (nicotinic acid): Has demonstrated 20–30% reductions in Lp(a) in clinical trials, but outcomes trials (AIM-HIGH, HPS2-THRIVE) did not demonstrate a cardiovascular benefit when added to statin therapy, and the drug carries significant side-effect burden. Currently not a standard recommendation.
PCSK9 inhibitors: Produce approximately 20–30% reductions in Lp(a) alongside large LDL reductions. Now guideline-supported in very high-risk patients.
RNA-targeted therapies (pelacarsen, olpasiran): These investigational agents are producing 70–90%+ reductions in Lp(a) in phase 2 and 3 trials and represent the most exciting frontier in Lp(a) management. Phase 3 outcomes data is anticipated in the mid-2020s.
Lipoprotein apheresis: Available in specialized centers for severely elevated Lp(a) with documented cardiovascular disease.
For most individuals with moderately elevated Lp(a), the clinical strategy is not to aggressively chase the Lp(a) number itself (currently difficult without advanced interventions) but to aggressively lower every other modifiable risk factor — LDL, inflammation, blood pressure, glycemia, and oxidative stress — to reduce the total cardiovascular burden that Lp(a) amplifies.
For more on supporting healthy LDL and inflammatory markers through lifestyle, see how omega-3 fatty acids support cardiovascular health.
How Ones Addresses This: What Your Formula Can Target
While no supplement directly lowers Lp(a) to a clinically meaningful degree, Ones formulas are designed to address the modifiable risk factors that determine how dangerous an elevated Lp(a) actually is in your body.
Based on your lab panel and wearable data, Ones' AI health practitioner may identify and act on the following relevant pathways:
Omega-3 (EPA/DHA) — Ones includes pharmaceutical-grade omega-3 at doses calibrated to your baseline hs-CRP and triglyceride levels. At 2,000+ mg EPA/DHA daily, omega-3 has been shown to reduce hs-CRP, lower triglycerides, and modestly reduce cardiovascular event risk in high-risk populations (Calder, British Journal of Nutrition 2012; PMID: 22591896). If your Lp(a) is elevated alongside a high hs-CRP, this is among the most evidence-supported interventions in your supplement toolkit.
CoQ10/Ubiquinol (200mg) — Oxidative stress at the endothelial level is one mechanism by which Lp(a) damages arterial walls. Ubiquinol, the reduced and more bioavailable form of CoQ10, supports mitochondrial energy production and acts as a potent lipid-phase antioxidant. Ones includes ubiquinol at 200mg — a dose consistent with clinical research — which may help reduce the oxidative burden that makes elevated Lp(a) more harmful.
Heart Support blend — Ones' proprietary Heart Support system blend brings together ingredients targeted at endothelial function and cardiovascular resilience. For users whose lab results show an elevated inflammatory cardiovascular risk profile — elevated CRP, borderline HbA1c, or elevated Lp(a) — this blend may be incorporated into the formula at the AI's discretion based on your specific findings.
Ones formulas come in 6 or 9-capsule daily plans, with the capsule count determined by the AI based on your complete health picture — not chosen by you at checkout. That specificity is what separates a data-driven formula from a generic multi. To understand how blood-based biomarkers like these translate into a personalized supplement plan, read more about how AI-powered lab interpretation works.
Always consult a physician or cardiologist before making changes to your cardiovascular management plan, particularly if your Lp(a) is above 125 nmol/L or you have existing cardiovascular disease.
Key Takeaways
- Optimal Lp(a) from a functional-medicine perspective is < 30 nmol/L (< 14 mg/dL) — significantly stricter than most conventional lab reference ranges.
- Lp(a) does not act alone: its cardiovascular impact is dramatically amplified by elevated hs-CRP (> 1.0 mg/L), fibrinogen (> 400 mg/dL), and HbA1c (> 5.7%), making companion marker interpretation essential.
- Lp(a) is 70–90% genetically determined — lifestyle and most supplements will not move the number significantly, so the clinical strategy focuses on lowering every other modifiable risk factor.
- Optimal hs-CRP is < 0.5–1.0 mg/L, optimal fibrinogen is 150–250 mg/dL, and optimal HbA1c from a functional standpoint is < 5.3% — all more conservative than standard lab flags.
- Omega-3 fatty acids and CoQ10/ubiquinol are among the best-supported supplement interventions for reducing the inflammatory and oxidative pathways that make elevated Lp(a) dangerous.
- RNA-targeted therapies (pelacarsen, olpasiran) represent the most promising clinical frontier for directly lowering Lp(a) by 70–90%, with outcomes trial results anticipated in the mid-2020s.